Foresee Pharmaceuticals Announces Completion of Casppian Phase 3 Study with Last Patient Last Visit and Confirms Topline Results: 94% of Patients Achieve LH Suppression with 6-Month Dosing Interval of Leuprolide Mesylate, also the acceptance of Casppian Study for Presentation at Endocrine Society, ENDO 2026 Medical Conference, as a Potential New Six-Month Treatment Option for Central Precocious Puberty